Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 3, 2009, Pages 425-432

  Henningsen, Kristoffer Mads Aaris ^a,c   Therkelsen, Susette Krohn ^a   Bruunsgaard, Helle ^a   Krabbe, Karen S ^a   Pedersen, Bente Klarlund ^a,b   Svendsen, Jesper Hastrup ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Atrial fibrillation; Electrical cardioversion; High sensitivity CRP; Inflammation; Interleukin 6

Indexed keywords

AMIODARONE; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; INTERLEUKIN 6; PROPAFENONE; SOTALOL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVERSION; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SINUS RHYTHM; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE;

EID: 67649690973     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802676848     Document Type: Article

References (28)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73.
2. Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (the Copenhagen city heart study). Am J Cardiol 2003;92:1419-23.
3. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomström-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-65.
4. Dahlin J, Svendsen P, Gadsboll N. Poor maintenance of sinus rhythm after electrical cardioversion of patients with atrial fibrillation or flutter: a five year follow-up of 268 consecutive patients. Scand Cardiovasc J 2003;37:324-8.
5. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91.
6. Engelmann M, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005;26: 2083-92.
7. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful electrical cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2005;108:346-53.
8. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, Vardas PE. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008;94:200-4.
9. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007;99:1421-4.
10. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
11. Lo B, Fijnheer R, Nierich AP, Bruins P, Kalkman CJ. C-reactive protein is a risk indicator for atrial fibrillation after myo-cardial revascularization. Ann Thorac Surg 2005;79:1530-5.
12. Fujiki A, Sakamoto T, Nishida K, Mizumaki K, Inoue H. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation. J Cardiovasc Pharmacol 2007;50:264-6.
13. Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Boje Jensen G. ANP and BNP in atrial fibrillation before and after cardioversion - and their relationship to cardiac volume and function. Int J Cardiol 2008;127:396-9.
14. Lombardi F, Colombo A, Basilico B, Ravaglia R, Garbin M, Vergani D, Battezzati PM, Fiorentini C. Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol 2001;38:1585-6.
15. Wijfels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
16. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
17. Climent V, Marín F, Mainar L, Roldán V, García A, Martínez JG, Lip GY. Influence of electrical cardioversion on inflammation and indexes of structural remodelling, in persistent atrial fibrillation. Int J Cardiol 2008. Epub ahead of print.
18. Roldán V, Marín F, Blann AD, García A, Marco P, Sogorb F, Lip GY. Interleukin-6, endothelial activation and thrombo-genesis in chronic atrial fibrillation. Eur Heart J 2003;24:1373-80.
19. Chen MC, Chang JP, Liu WH, Yang CH, Chen YL, Tsai TH, Wang YH, Pan KL. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol 2008;102:861-5.
20. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jönsson A, Säfström K, Walfridsson H. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008;10:848-53.
21. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007;120:85-91.
22. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-7.
23. Holm T, Andreassen AK, Ueland T, Kjekshus J, Frøland SS, Kjekshus E, Simonsen S, Aukrust P, Gullestad L. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 2001;87:815-18.
24. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106: 1447-52.
25. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
26. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
27. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35.
28. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007;50: 2021-8.